证券代码：688488 证券简称：艾迪药业 公告编号：2025-020 （二）本年度募集资金使用和结余情况 截至 2024 年 12 月 31 日止，公司募集资金使用及结存情况如下： 江苏艾迪药业股份有限公司 关于 2024 年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》等法律法规的规定，江苏艾迪药业股份有限公 司（以下简称"公司"、"艾迪药业"）董事会编制了公司 2024 年度募集资金存放 与实际使用情况的专项报告，具体情况如下： 一、募集资金基本情况 （一）首次公开发行股票募集资金情况 经中国证券监督管理委员会出具《关于同意江苏艾迪药业股份有限公司首次 公开发行股票注册的批复》（证监许可〔2020〕1185 号）核准，公司向社会公开 发行人民币普通股 6,000 万股，发行价为每股人民币 13.9 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-017 江苏艾迪药业股份有限公司 关于 2024 年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日召开 第三届董事会第三次会议、第三届监事会第三次会议，审议通过了《关于 2024 年度计提资产减值准备的议案》，现将有关事项公告如下： 一、计提资产减值准备的情况概述 根据《企业会计准则》以及公司会计政策、会计估计的相关规定，为了真实、 准确地反映公司截至 2024 年 12 月 31 日的财务状况，本着谨慎性原则，公司对 截至 2024 年 12 月 31 日公司及下属子公司的资产进行了减值测试，对可能发生 资产减值损失的相关资产计提减值准备。2024 年度确认的资产减值损失和信用 减值损失总额为 6,260.79 万元。具体情况如下表所示： 单位：万元人民币 | | 项目 | 本期发生额 | 备注 | | --- | --- | --- | --- | | ...

江苏艾迪药业股份有限公司 2024 年度会计师事务所履职情况评估报告 江苏艾迪药业股份有限公司（以下简称"公司"）聘请公证天业会计师事务 所（特殊普通合伙）（以下简称"公证天业"）作为公司 2024 年度财务报告审计 机构及内部控制审计机构。根据财政部、国务院国有资产监督管理委员会、中国 证券监督管理委员会颁布的《国有企业、上市公司选聘会计师事务所管理办法》， 公司对公证天业 2024 年度审计过程中的履职情况进行评估。经评估，公司认为， 公证天业在资质等方面合规有效，履职能够保持独立性，勤勉尽责，公允表达意 见。具体情况如下： 一、2024 年度会计师事务所基本情况 （一）会计师事务所基本情况 1、基本信息 （1）会计师事务所名称：公证天业会计师事务所（特殊普通合伙） （2）成立日期：公证天业创立于 1982 年，是全国首批经批准具有从事证券、 期货相关业务资格及金融业务审计资格的会计师事务所之一。2013 年 9 月 18 日， 转制为特殊普通合伙企业 （3）组织形式：特殊普通合伙企业 （4）注册地址：无锡市太湖新城嘉业财富中心 5-1001 室 （5）首席合伙人：张彩斌 （6）截至 2024 年末，公证 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-016 江苏艾迪药业股份有限公司 关于召开2024年年度股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2024年年度股东会 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 5 月 20 日 15 点 00 分 召开地点：南京市玄武区玄武大道 699-18 号百家汇创新社区 20 栋 5 楼 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 20 日至2025 年 5 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投 ...

二、监事会会议审议情况 与会监事就如下议案进行了审议，并表决通过以下事项： 1、审议通过《关于公司<2024 年度监事会工作报告>的议案》 公司监事会认为：2024 年，公司监事会按照《中华人民共和国公司法》《上 市公司治理准则》《上海证券交易所科创板股票上市规则》等法律、法规及规范 性文件，并依照《公司章程》和《监事会议事规则》的规定，认真履行职责。本 年度公司监事会共召开 9 次会议，对公司重大决策和决议的形成、表决程序进行 了监督和审查，对公司依法合规运作进行了检查，特别是对公司经营活动、财务 状况、股东会召开程序以及董事、高级管理人员履行职责情况等方面实施了有效 监督，保障了公司全体股东权益、公司利益以及员工的合法权益，促进了公司的 规范化运作。 证券代码：688488 证券简称：艾迪药业 公告编号：2025-014 江苏艾迪药业股份有限公司 第三届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 江苏艾迪药业股份有限公司（以下简称"公司"）第三届监事会第三次会议 通 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-015 公司董事会认为：2024年，公司总经理按照有关规定认真履行职责，紧密围 绕着公司的发展战略，扎实推动研发、生产、销售、经营管理等各项工作，同意 通过此议案。 表决结果：同意票7票，占董事总数100%；反对票0票，占董事总数0%；弃 权票0票，占董事总数0%。 （二）审议通过《关于公司<2024年度董事会工作报告>的议案》 公司董事会认为：2024年度，公司董事会严格遵守《中华人民共和国公司法》 《中华人民共和国证券法》等法律、法规、规范性文件及《公司章程》的规定， 认真履行股东会赋予的职责，规范运作，科学决策，积极推动公司各项业务发展， 同意通过此议案。 江苏艾迪药业股份有限公司 第三届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 江苏艾迪药业股份有限公司（以下简称"公司"）第三届董事会第三次会议 通知于 2025 年 4 月 19 日以书面或邮件方式送达全体董事，会议于 2025 年 4 月 29 ...

Financial Performance - The company reported a profit distribution plan for 2024, which includes no cash dividends, no bonus shares, and no capital reserve conversion into shares[4]. - The company has not achieved profitability since its listing, indicating ongoing financial challenges[3]. - The company's operating revenue for 2024 was CNY 417.80 million, a 1.57% increase from CNY 411.36 million in 2023[22]. - The net profit attributable to shareholders for 2024 was a loss of CNY 141.20 million, compared to a loss of CNY 76.07 million in 2023, representing an 85.63% decrease year-over-year[22][24]. - The net cash flow from operating activities for 2024 was a negative CNY 37.50 million, an improvement from a negative CNY 166.22 million in 2023[22]. - The company's total assets increased by 7.04% to CNY 1.87 billion at the end of 2024, up from CNY 1.75 billion at the end of 2023[23]. - The basic earnings per share for 2024 was CNY -0.34, a decrease of 88.89% compared to CNY -0.18 in 2023[22]. - The weighted average return on net assets for 2024 was -13.42%, a decrease of 6.86 percentage points from -6.56% in 2023[22]. - The company reported a non-recurring loss of 55.70 million yuan from the disposal of non-current assets in 2023[28]. - The company received government subsidies amounting to 25.79 million yuan in the reporting period, down from 63.39 million yuan in the previous year[29]. - The company's total revenue for the reporting period was CNY 41,780.47 million, an increase of 1.57% compared to the previous year[178]. - The net profit attributable to shareholders was CNY -14,120.43 million, a decrease of 85.63% year-on-year[178]. Research and Development - Research and development expenses accounted for 25.73% of operating revenue in 2024, an increase of 5.27 percentage points from 20.46% in 2023[22][24]. - The total R&D investment for the year was approximately ¥107.5 million, representing a 27.70% increase compared to the previous year[141]. - The proportion of total R&D investment to operating income increased by 5.27 percentage points to 25.73%[141]. - The company has 27 ongoing research projects, including 7 Class 1 new drugs and 3 Class 2 new drugs, with two Class 1 innovative HIV drugs, AINOVIR and AINOMITE, approved and commercialized[61]. - The company is focusing on the development of long-acting HIV drugs, with ongoing preclinical research on lead compounds[144]. - The company has achieved significant advancements in the synthesis of key raw materials for drugs ACC007, ACC010, ACC015, and ACC017, focusing on high purity and low-cost production methods[136]. - The company has established a small molecule drug research and development platform and a human-derived protein research and development platform, focusing on project management and technical development[92]. - The company has completed the small-scale development of a single-tablet regimen for HIV patients, enhancing convenience for treatment[146]. - The company has developed multiple formulation technologies, including ACC008, which addresses solubility and stability issues of active ingredients[137]. - The company has completed enrollment for all subjects in a Phase Ib/IIa clinical study for initial HIV-infected patients, with preliminary results indicating good safety and clear efficacy of the ACC017 tablet[158]. Product Development and Innovation - The company is in the process of developing new products and technologies, although specific details were not provided in the summary[5]. - The company is actively advancing its research pipeline, with the ACC017 integrase inhibitor I phase clinical trial progressing smoothly and a patent granted[36]. - The company is developing a combination formulation centered on ACC017, which has completed small-scale and pilot studies and is advancing towards IND registration[37]. - The company is focusing on enhancing its innovation capabilities in the HIV treatment sector, aiming to meet the urgent domestic demand for HIV treatment[33]. - The company is committed to building a global industry layout based on its core areas of HIV antiviral and human protein[34]. - The company is actively pursuing clinical trials and regulatory approvals for its innovative drug candidates, positioning itself for future market expansion[136]. - The company has developed a proprietary technology for the preparation of epidermal growth factor from urine, enhancing its product portfolio in regenerative medicine[135]. - The company has established preliminary quality standards for long-acting low molecular weight heparin sodium freeze-dried powder injections, with a total investment of 15,000,000.00 RMB[150]. - The company has completed the production batch verification for ACC017 and is progressing with stability studies[144]. - The company has achieved a significant milestone with the completion of raw material drug process development for high molecular weight urokinase, with clinical research ongoing[146]. Market and Sales Performance - The total sales revenue from HIV new drugs reached CNY 149.9 million, representing a year-on-year growth of 103.73%, indicating positive progress in commercialization efforts[48]. - The revenue from the HIV new drug Aino Mite tablet reached CNY 133.54 million, a significant increase of 173.41% year-on-year[186]. - The sales volume of Urokinase crude product decreased by 24.07%, while inventory increased by 81.25%[189]. - The production volume of Aino Mite tablet increased by 185.39%, with sales volume rising by 127.07%[190]. - The company has strengthened its position in the domestic HIV innovative drug market, becoming one of the leading enterprises in this sector[123]. - The company is actively expanding its international business, with ongoing audits of overseas suppliers and the gradual development of business collaborations[51]. - The company has established a marketing strategy focused on "medical guidance, market pull, and sales implementation," enhancing brand recognition and product accessibility[165]. - The company is actively expanding its overseas market presence, particularly in Africa and Southeast Asia, to create new business growth points[166]. - The company plans to continue the commercialization of its HIV new drug and expand into overseas markets in 2025[170]. - The company is focused on promoting new products and expanding market reach following recent acquisitions and product approvals[186]. Compliance and Governance - The company has received a standard unqualified audit report from the accounting firm, ensuring the accuracy of the financial statements[4]. - There are no non-operating fund occupations by controlling shareholders or related parties, indicating financial integrity[6]. - The company has not violated decision-making procedures for external guarantees, ensuring compliance with regulations[7]. - The company has not disclosed any special arrangements in corporate governance, suggesting standard practices are in place[8]. - The company emphasizes the affordability of its innovative drugs, contributing to reduced patient burden and significant savings for national healthcare funds[74]. Risks and Challenges - The company has outlined various risk factors in its operations, which investors should consider when making investment decisions[3]. - The company faces risks related to the commercialization of its innovative drugs and potential delays in project implementation[174]. - The company has not provided specific future performance guidance or projections, reflecting a cautious outlook[5]. - The company has reported a 66.59% decrease in labor costs for urine activator crude products compared to the previous year[193]. - The company did not report any significant changes or adjustments in its business, products, or services during the reporting period[196].

Financial Performance - The company's operating revenue for Q1 2025 reached ¥197,860,545.62, representing a 113% increase compared to ¥92,893,957.00 in the same period last year[4] - Net profit attributable to shareholders was ¥15,581,976.25, a significant turnaround from a loss of ¥13,606,889.35 in the previous year[4] - The net cash flow from operating activities improved to ¥39,754,170.62, compared to a negative cash flow of ¥70,322,344.42 in the same period last year[4] - Basic and diluted earnings per share increased to ¥0.04, up from a loss of ¥0.03 per share in the previous year[4] - The company achieved a total operating revenue of CNY 197.86 million in Q1 2025, a significant increase of 112.6% compared to CNY 92.89 million in Q1 2024[23] - The operating profit for Q1 2025 was CNY 31,827,713.39, a turnaround from an operating loss of CNY 16,860,520.56 in the same period last year[24] - Total comprehensive income for Q1 2025 was CNY 25,609,979.12, compared to a comprehensive loss of CNY 13,606,889.35 in Q1 2024[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,895,106,059.27, a 1.37% increase from ¥1,869,563,338.32 at the end of the previous year[5] - The company’s total assets reached CNY 1.90 billion as of March 31, 2025, compared to CNY 1.87 billion at the end of 2024, indicating a growth of 1.3%[20] - The company’s total liabilities were CNY 802.64 million as of March 31, 2025, slightly up from CNY 802.48 million at the end of 2024, reflecting a marginal increase of 0.2%[22] Research and Development - Research and development expenses totaled ¥19,484,687.54, accounting for 9.85% of operating revenue, down from 21.87% in the previous year, a decrease of 12.02 percentage points[5] - Research and development expenses decreased to CNY 15,711,444.19 in Q1 2025 from CNY 17,748,750.48 in Q1 2024, reflecting a reduction of about 11.5%[24] - The company is developing long-acting innovative HIV drugs and has completed pre-toxicology tests for a new molecule[16] - The company has initiated IND registration for a long-acting new molecule and completed the production of validation batches[15] - The company is expanding its pipeline for pre-exposure prophylaxis in the HIV field, focusing on long-acting drug development[16] Market and Product Development - The increase in operating revenue was primarily due to the consolidation of Nanjing Nanda Pharmaceutical Co., which contributed an additional ¥92,237,500 in revenue, and a rise in HIV drug business revenue by ¥27,010,700[7] - Revenue from the HIV new drug business reached CNY 62.72 million, marking a year-on-year increase of 75.64%[12] - The company successfully established a commercial operation system for HIV innovative drugs, integrating product characteristics with market demand[12] - The phase III clinical trial of the drug Ainomi has shown positive results, with over 95% adherence and viral suppression rates maintained from 0 to 144 weeks[13] - The new integrase inhibitor ACC017 has received a patent and is progressing to phase II clinical trials, with initial results indicating good safety and efficacy[14] - The company has completed the enrollment of participants for a phase II clinical study in treatment-experienced populations[15] - The company is actively promoting its new drug pipeline and enhancing its market presence through strategic adjustments and team building[12] - The company is actively expanding its overseas market for HIV innovative products and human protein products, with a focus on Africa and Southeast Asia[17] Cash Flow and Financial Health - The company’s cash and cash equivalents increased to CNY 422.73 million as of March 31, 2025, compared to CNY 335.34 million at the end of 2024, reflecting a growth of 25.9%[20] - The company’s accounts receivable stood at CNY 127.35 million as of March 31, 2025, slightly down from CNY 139.14 million at the end of 2024, a decrease of 8.5%[20] - The company’s inventory increased to CNY 271.74 million as of March 31, 2025, compared to CNY 254.97 million at the end of 2024, representing a growth of 6.6%[20] - The company raised CNY 200,000,000.00 through borrowings in Q1 2025, compared to CNY 140,300,000.00 in Q1 2024[27] - The company reported an investment income loss of CNY 225,518.40 in Q1 2025, contrasting with a gain of CNY 7,573,963.00 in Q1 2024[24] - The company’s sales expenses increased to CNY 57,867,148.60 in Q1 2025 from CNY 21,191,476.67 in Q1 2024, marking an increase of approximately 173%[24]

江苏艾迪药业股份有限公司 关于提请股东会授权董事会以简易程序向特定对象 发行股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688488 证券简称：艾迪药业 公告编号：2025-019 江苏艾迪药业股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日召开 的第三届董事会第三次会议审议通过了《关于提请股东会授权董事会以简易程序 向特定对象发行股票的议案》，本议案尚需提交公司股东会审议通过。具体情况 如下： 根据《上市公司证券发行注册管理办法》等相关规定，公司董事会提请股东 会授权董事会决定公司择机向特定对象发行融资总额不超过人民币三亿元且不 超过最近一年末净资产百分之二十的股票，授权期限自公司 2024 年年度股东会 审议通过之日起至公司 2025 年年度股东会召开之日止。本次以简易程序向特定 对象发行股票（以下简称"本次发行"）授权事宜包括但不限于以下内容： 一、确认公司是否符合以简易程序向特定对象发行股票条件 授权董事会根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司证 ...

公证天业会计师事务所（特殊普通合伙） 关于江苏艾迪药业股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：江苏艾迪药业股份有限公司 审计单位：公证天业会计师事务所（特殊普通合伙） 联系电话：0510-68798988 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP Wuxi, Jiangsu, China 四国 行其 景观 Tel: 86 (510) 68798988 (510) 6879898 Fax: 86 (510) 68567788 E-mail: mail@gztycpa.cn 关于江苏艾迪药业股份有限公司 非经营性资金占用及其他关联资金往来情况的专项说明 苏公W[2025]E1323号 江苏艾迪药业股份有限公司全体股东: 我们接受委托,按照中国注册会计师审计准则审计了江苏艾迪药业股份有限公 司(以下简称"贵公司")财务报表,包括2024年12月31日的合并及母公司资产 负债表,2024年度的合并及母公司利润表、合并及母公司现金流量表、 ...